Pediatric ObesityFAMENCT06391671
The Stress-obesity Axis: a Metabolomics Approach Towards Personalized Nutrition in Adolescents
An observational study of Pediatric Obesity, run by University Ghent at 7 sites in Belgium.
Trial summary
The ultimate aim of this project is to establish a validated strategy that allows for personalized intervention in adolescents (11 to 17 years) whom are assigned a state of overweight or obesity. Read more about this study
- Who is it for?
- Ages 11 to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Pediatric Obesity
- What is being tested?
- Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)
- How many people
- 750 participants
- Where
- 7 sitesBelgium
- Study dates
- 11 Jan 2022to Jul 2027
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 11 to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: Volunteers with normall weight and overweight/obesity are being recruited from several hospitals (UZ Ghent, AZ Jan Palfijn, UZ Antwerpen, ZNA Middelheim, AZ Delta Roeselare, UZ Brussel, UZ Leuven, Onze-Lieve-Vrouw Ziekenhuis Aalst, AZ Sint-Lucas Brugge, AZ Sint-Elizabeth Zottegem, Zeepreventorium, Clairs Vallons) and schools (Don-Bosco Sint-Denijs-Westrem, Leiepoort Deinze, Broederschool Sint-Niklaas, SFI Melle) in Belgium
Who may be able to join
- Age 11-17 years
Who cannot join
- Obesity/overweight
- Type 1 diabetes
- Medical conditions including pancreatic failure
- Developmental and hormonal disorders. E.g. thyroid problems, adrenal problems, Kallmann's syndrome, Klinefelter's syndrome, Prader-Willi syndrome (PWS), Congenital hypogonadotropic hypogonadism (CHH), ...
- Pregnancy
- In treatment with systemic concentrations of corticosteroids (cortisone). Eg cortisone/betamethasone/Dexamethasone/Fludrocortisone/Hydrocortisone in pill form or administration by injections.
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
Belgium7 sites, 7 recruiting
- Recruiting
UZ Antwerpen
Antwerp, 2000
Karolien Van de Maele, Prof, +32 3 821 32 51, karolien.vandemaele@uza.be
- Recruiting
ZNA Middelheim
Antwerp, 2000
Daniel Klink, Dr, daniel.klink@zna.be
- Recruiting
Zeepreventorium
De Haan, West-Vlaanderen, 8420
Ann Tanghe, Ann.tanghe@zeepreventorium.be
- Recruiting
AZ Jan Palfijn Gent, Oost-Vlaanderen, Belgium, 9000
Ghent, Oost-Vlaanderen, 9000
Nele Baeck, Dr, Nele.Baeck@janpalfijngent.be
- Recruiting
Ghent University Hospital
Ghent, Oost-Vlaanderen, 9000
Stefaan de Henauw, Prof, +32 9 332 36 79, Stefaan.deHenauw@UGent.be
- Recruiting
Clairs Vallons
Ottignies-Louvain-la-Neuve, Waals Brabant, 1340
Laure Joachim, Dr, laurejoachim@clairsvallons.be
- Recruiting
AZ Delta
Roeselare, West-Vlaanderen, 8800
Els Ide, dr, els.ide@azdelta.be
About this study
Official title: The Stress-obesity Axis: a Metabolomics Approach Towards Personalized Nutrition in Adolescents (FAME)
The ultimate aim of this project is to establish a validated strategy that allows for personalized intervention in adolescents (11 to 17 years) whom are assigned a state of overweight or obesity.
The investigators will assess the following hypotheses:
Read more
- Weight condition is reflected by the fecal metabolome (WP1)
- Emotional stress is implicated in weight condition (WP1)
- Functionality of the gut microbiome is related to the diet-stress-obesity axis (WP2)
- Dietary pattern impacts the fecal metabolome and gut microbiome (WP2)
- Personalized dietary intervention outperforms generalized dietary approaches (WP3)
Participants will:
- Produce a saliva, stool and hair sample
- Fill in questionnaires regarding mental health, medical health and demographic information
- Fill in a food frequency questionnaire and a 24-hrecalls
- Be measured (height, weight, fat% and waist circumference)
The samples will be analyzed using a technique called metabolomics to identify biomarker candidates with diagnostic and/or prognostic potential. Additionally, microbiome analysis will be performed to map the microbiome of all groups.
Read the detailed description
In WP1, the investigators will assess the metabolic mechanisms underlying the obesity pathology in adolescents, whereby the involvement of emotional stress, will be of particular interest. To this end, a dual strategy fecal metabolomics will be performed: targeted profiling and untargeted fingerprinting. A major objective in this respect is to metabolically segregate between the overweight/obesity and normal weight condition as well as to reveal metabolic singularities that specifically relate to emotional stress. Fecal material, saliva and a hair sample will be collected from adolescents (11 to 17 years). Assignment of a participant's stress state will be performed post-hoc and based on hair cortisol concentrations and scores from the psychological questionnaires. The samples will be collected at home and have to be frozen immediately after sample collection. The samples will be analyzed using a technique called metabolomics, using UHPLC-HRMS (Ultra-High Performance Liquid Chromatography coupled to High-Resolution Mass Spectrometry).
In WP2 the investigators will assess the microbiome and diet as drivers for obesity. Fecal samples will be subjected to DNA extraction and whole-metagenome shotgun sequencing will be performed using the Illumina HiSeq 2500 system (151 bp paired-end reads; Novogene). In order to collect data about both long- and short-term dietary intakes, participants will be provided with a FFQ and a 24-h recall.
Eventually, discovery of metabolite marker signatures and elucidation of mechanistic pathways will offer opportunities to stratify obese adolescents according to emotional stress status, microbial composition and dietary preferences.
In WP3, the new data from WP1/2 will be translated in personalized dietary recommendations. The investigators will assess the potential of dietary interventions focused on nutrient quality (not energy-reduced) to affect the stress-obesity axis directly or by gut microbial modulation. After ethical approval, the dietary intervention study will include up to 20 individuals that were allocated to the overweight/obesity group. In our 3-month personalized intervention, separate menus for each participant will be prepared by our dietician. Based on WP1/2 and literature evidence, appropriate changes in nutrients will be aimed for. At different points in time, fecal samples will be collected, aliquoted and biobanked at -80°C. Fecal samples will be used for polar metabolomics and lipidomics analyses and microbiome metasequencing. At the start and after the 3-months intervention, fasting blood samples will be taken for clinical biomarkers (glucose, insulin, cholesterol, cytokines, ...). In addition, indirect calorimetry will determine resting energy expenditure. Anthropometric measures include BMI, waist and fat%. Questionnaires cover emotional eating (DEBQ), satiety, physical activity, sleep and quality-of-life (KINDL). Study volunteers will be asked to fill out an FFQ and 3-day 24-h recall to assess dietary habits prior to the trial.
- Conditions
- Pediatric Obesity
- Being tested
- Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)
- Keywords
- Metabolomic, Mass spectrometry
- Medical subject headings
- Pediatric Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)Other
Saliva and feces are collected at the families home. A questionnaire is filled in by the participant (psychological) and parents (demographical and medical info). Upon consultation we are collecting anthropometric data (date of birth, length, weight, abdominal circumference, Tanner pubertal stage, etc.)
| Study group | Role | What they receive |
|---|---|---|
| Overweight/obese | BMI-Z > 25 Receives: Other: Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data) | |
| Normal weight | BMI-Z < 25 Receives: Other: Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Metabolomics
Saliva and fecal samples will be analyzed using a technique called metabolomics, which analyses all small molecules (metabolites) present in a biological fluid. These metabolites will be used to find biomarkers that are related to the disease and could have diagnostic or prognostic potential. Additionally, these metabolites could give more insights into the development and maintenance of the disease.
Measured: Samples will be analyzed in the 4th quarter of 2024.
Secondary outcomes (3)
Microbiome analysis
The microbiomes of all groups will be analyzed because it has been described in literature that the microbiome can differ between healthy and obese individuals
Measured: Microbiome analyses will be performed at the start of 2025
Stress levels
Assignment of a participant's stress state will be performed based on hair cortisol concentrations, and scores from the Perceived Stress Scale (PSS), the Children's Depression Inventory 2 (CDI-2) and the Rosenberg Self-Esteem Scale (RSES) questionnaires. A summary chronic stress variable will be calculated by adding up the four z-score-transformed variables to give them equal weight
Measured: Hair cortisol analyses will be conducted in the first quarter of 2025. Data processing of the questionnaires is an ongoing process, to be completed by the last quarter of 2024
Food frequency questionnaire
To collect data about dietary intakes, participants are provided with an FFQ. Participants are required to indicate the frequency of consumption for each food of interest, ranging from (almost) never, to a few times a week, (almost) daily, to multiple times a day. All responses are encoded into numerical values, representing the frequency of consumption for specific foods.
Measured: FFQ data are being analyzed continuously and will be finished when the sample collection is finished (estimated by the end of 2024)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Apr 2024
- Study start11 Jan 2022
- Primary completionJul 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pediatric ObesityStudies of the same condition, open and under way.
- More trials run by University GhentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 750 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- University Ghent
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Stefaan de Henauw, Prof, Principal investigator, University Hospital, Ghent
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06391671
- Sponsor's protocol ID
- BC-10583
- Acronym
- FAME
- Status last verified
- Apr 2024
- First submitted
- 19 Apr 2024
- Last updated
- 30 Apr 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with other researchers
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Stress-obesity Axis: a Metabolomics Approach Towards Personalized Nutrition in Adolescents (FAME)
- ClinicalTrials.gov ID
- NCT06391671
- Acronym / sponsor ID
- FAME / BC-10583
- Conditions
- Pediatric Obesity
- Keywords
- Metabolomic, Mass spectrometry
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 750 participants (estimated)
- Lead sponsor
- University GhentUniversity, hospital or other
- Study start
- 11 Jan 2022 (actual)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 30 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The ultimate aim of this project is to establish a validated strategy that allows for personalized intervention in adolescents (11 to 17 years) whom are assigned a state of overweight or obesity.
The investigators will assess the following hypotheses:
- Weight condition is reflected by the fecal metabolome (WP1)
- Emotional stress is implicated in weight condition (WP1)
- Functionality of the gut microbiome is related to the diet-stress-obesity axis (WP2)
- Dietary pattern impacts the fecal metabolome and gut microbiome (WP2)
- Personalized dietary intervention outperforms generalized dietary approaches (WP3)
Participants will:
- Produce a saliva, stool and hair sample
- Fill in questionnaires regarding mental health, medical health and demographic information
- Fill in a food frequency questionnaire and a 24-hrecalls
- Be measured (height, weight, fat% and waist circumference)
The samples will be analyzed using a technique called metabolomics to identify biomarker candidates with diagnostic and/or prognostic potential. Additionally, microbiome analysis will be performed to map the microbiome of all groups.
Detailed description
In WP1, the investigators will assess the metabolic mechanisms underlying the obesity pathology in adolescents, whereby the involvement of emotional stress, will be of particular interest. To this end, a dual strategy fecal metabolomics will be performed: targeted profiling and untargeted fingerprinting. A major objective in this respect is to metabolically segregate between the overweight/obesity and normal weight condition as well as to reveal metabolic singularities that specifically relate to emotional stress. Fecal material, saliva and a hair sample will be collected from adolescents (11 to 17 years). Assignment of a participant's stress state will be performed post-hoc and based on hair cortisol concentrations and scores from the psychological questionnaires. The samples will be collected at home and have to be frozen immediately after sample collection. The samples will be analyzed using a technique called metabolomics, using UHPLC-HRMS (Ultra-High Performance Liquid Chromatography coupled to High-Resolution Mass Spectrometry).
In WP2 the investigators will assess the microbiome and diet as drivers for obesity. Fecal samples will be subjected to DNA extraction and whole-metagenome shotgun sequencing will be performed using the Illumina HiSeq 2500 system (151 bp paired-end reads; Novogene). In order to collect data about both long- and short-term dietary intakes, participants will be provided with a FFQ and a 24-h recall.
Eventually, discovery of metabolite marker signatures and elucidation of mechanistic pathways will offer opportunities to stratify obese adolescents according to emotional stress status, microbial composition and dietary preferences.
In WP3, the new data from WP1/2 will be translated in personalized dietary recommendations. The investigators will assess the potential of dietary interventions focused on nutrient quality (not energy-reduced) to affect the stress-obesity axis directly or by gut microbial modulation. After ethical approval, the dietary intervention study will include up to 20 individuals that were allocated to the overweight/obesity group. In our 3-month personalized intervention, separate menus for each participant will be prepared by our dietician. Based on WP1/2 and literature evidence, appropriate changes in nutrients will be aimed for. At different points in time, fecal samples will be collected, aliquoted and biobanked at -80°C. Fecal samples will be used for polar metabolomics and lipidomics analyses and microbiome metasequencing. At the start and after the 3-months intervention, fasting blood samples will be taken for clinical biomarkers (glucose, insulin, cholesterol, cytokines, ...). In addition, indirect calorimetry will determine resting energy expenditure. Anthropometric measures include BMI, waist and fat%. Questionnaires cover emotional eating (DEBQ), satiety, physical activity, sleep and quality-of-life (KINDL). Study volunteers will be asked to fill out an FFQ and 3-day 24-h recall to assess dietary habits prior to the trial.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Target follow-up
- 3 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Overweight/obese | – | Other: Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)BMI-Z > 25 |
| Normal weight | – | Other: Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)BMI-Z < 25 |
Who may qualify
- Ages
- 11 to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- Volunteers with normall weight and overweight/obesity are being recruited from several hospitals (UZ Ghent, AZ Jan Palfijn, UZ Antwerpen, ZNA Middelheim, AZ Delta Roeselare, UZ Brussel, UZ Leuven, Onze-Lieve-Vrouw Ziekenhuis Aalst, AZ Sint-Lucas Brugge, AZ Sint-Elizabeth Zottegem, Zeepreventorium, Clairs Vallons) and schools (Don-Bosco Sint-Denijs-Westrem, Leiepoort Deinze, Broederschool Sint-Niklaas, SFI Melle) in Belgium
Key inclusion criteria (1 listed)
- Age 11-17 years
Key exclusion criteria (6 listed)
- Obesity/overweight
- Type 1 diabetes
- Medical conditions including pancreatic failure
- Developmental and hormonal disorders. E.g. thyroid problems, adrenal problems, Kallmann's syndrome, Klinefelter's syndrome, Prader-Willi syndrome (PWS), Congenital hypogonadotropic hypogonadism (CHH), ...
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)Saliva and feces are collected at the families home. A questionnaire is filled in by the participant (psychological) and parents (demographical and medical info). Upon consultation we are collecting anthropometric data (date of birth, length, weight, abdominal circumference, Tanner pubertal stage, etc.) | Other | Normal weight, Overweight/obese |
Primary outcome
Metabolomics
Time frame: Samples will be analyzed in the 4th quarter of 2024.
Saliva and fecal samples will be analyzed using a technique called metabolomics, which analyses all small molecules (metabolites) present in a biological fluid. These metabolites will be used to find biomarkers that are related to the disease and could have diagnostic or prognostic potential. Additionally, these metabolites could give more insights into the development and maintenance of the disease.
3 secondary outcomes
Microbiome analysis
Time frame: Microbiome analyses will be performed at the start of 2025
Stress levels
Time frame: Hair cortisol analyses will be conducted in the first quarter of 2025. Data processing of the questionnaires is an ongoing process, to be completed by the last quarter of 2024
Food frequency questionnaire
Time frame: FFQ data are being analyzed continuously and will be finished when the sample collection is finished (estimated by the end of 2024)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2024.
- Individual participant dataSharing planned: No. Individual participant data will not be shared with other researchers
Related trials for Pediatric Obesity
Not yet recruiting
Effectiveness of a 10-week Multicomponent Intervention Combined With Parent Education on Binge Eating Behavior in Children and Adolescents
Binge Eating Disorder, Binge Eating
RecruitingPhase 3
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Obesity
Recruiting
National Childhood Obesity Prevention Programme BE FIT 24
Childhood Obesity
RecruitingPhase 2
Oxytocin for Weight Loss in Adolescents
Obesity, Adolescent, Oxytocin
RecruitingPhase 3
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stefaan de Henauw, Prof principal investigator
University Hospital, Ghent
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pediatric Obesity, run by University Ghent at 7 sites in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Emile Callemeyn, Dr (+32473271636, emile.callemeyn@ugent.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Metabolomics (time frame: Samples will be analyzed in the 4th quarter of 2024.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2024; AzTrials last refreshed its copy on 7 Nov 2026.